Compare NGEN & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NGEN | EIC |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 228.8M |
| IPO Year | 2018 | 2018 |
| Metric | NGEN | EIC |
|---|---|---|
| Price | $1.86 | $10.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $18.00 | $12.63 |
| AVG Volume (30 Days) | ★ 375.0K | 87.7K |
| Earning Date | 04-02-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $9.17 |
| 52 Week High | $5.93 | $13.92 |
| Indicator | NGEN | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 46.72 |
| Support Level | $1.59 | $9.84 |
| Resistance Level | $2.22 | $10.15 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 95.35 | 33.93 |
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.